COMMUNIQUÉS West-GlobeNewswire

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

28/04/2025 - 15:23

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented [...]

CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

28/04/2025 - 15:53

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings [...]

Baylor Genetics Joins Child Neurology Society as Official Genetic Testing Partner

28/04/2025 - 16:00

Partnership underscores Baylor Genetics’ commitment to providing genetic testing as an important step to end the diagnostic odyssey for patients and families facing neurodevelopmental disorders HOUSTON, April 28, 2025 ( [...]

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28/04/2025 - 11:00

- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time [...]

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

28/04/2025 - 12:00

DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine [...]

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

28/04/2025 - 12:45

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – [...]

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

28/04/2025 - 12:50

- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton [...]

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

28/04/2025 - 13:00

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced [...]

Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated Patients

28/04/2025 - 13:00

EXTON, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events. Speakers will demonstrate how novel interventional [...]

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening

28/04/2025 - 13:00

LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and [...]

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)

28/04/2025 - 13:00

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people in the European [...]

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

28/04/2025 - 13:00

WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs [...]

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

28/04/2025 - 13:00

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report [...]

Cannara Biotech affiche des résultats record au deuxième trimestre et accélère son expansion nationale

28/04/2025 - 13:00

Revenus records : Revenus nets de 26,6 millions de dollars au deuxième trimestre de 2025, soit une augmentation de 35 % par rapport aux 19,7 millions de dollars du deuxième trimestre de 2024, grâce à la croissance [...]

Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates

28/04/2025 - 13:00

Record Revenue: Net revenues of $26.6 million in Q2 2025, a 35% increase compared to $19.7 million in Q2 2024, driven by national brand growth and product innovation. Record Profitability: Gross profit before fair value [...]

XORTX Announces Grant of European Patent

28/04/2025 - 13:00

Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | [...]

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

28/04/2025 - 13:00

BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a [...]

Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting

28/04/2025 - 13:00

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today [...]

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

28/04/2025 - 13:00

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both adaptive and innate anti [...]